A multicenter retrospective analysis of M0/M1 CRPC patients with pre- or post-docetaxel androgen receptor axis-targeted treatment showed that NLR ≥ 2.5 is an independent risk factor for poorer cancer-specific survival (CSS) and rPFS [51]. This evidence concerns the gene AR and cancer.